Drug intelligence / Profile preview

CM-2489

Development stage: Discontinued
Lead developer: CalciMedica
Modality: Small Molecules
Administration: Oral

Overview

CM-2489 is an oral small-molecule inhibitor of calcium-release activated calcium (CRAC) channels developed by CalciMedica for immune and inflammatory disorders, notably moderate-to-severe plaque psoriasis. It selectively targets store-operated calcium entry mediated by the ORAI1 channel and its activator STIM1, thereby suppressing T-cell activation and downstream cytokine production, and functions as a first-in-class CRAC channel inhibitor that completed Phase I clinical evaluation before development was discontinued.

Other names: CRAC channel inhibitor - CalciMedica

Targets

ORAI1 (Calcium release–activated calcium channel protein 1)

Beyond the preview

Go deeper on CM-2489.

Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from study design and recruitment through results.

Trial phase
Status
Readouts

Indications & development

Explore development by indication, patient population, and geography.

Indications
Development status
Countries

Licensing & deals

Trace asset ownership, licensing agreements, and commercial partnerships.

Partners
Deal terms
Milestones

Patents & exclusivity

Explore the patent landscape and regulatory exclusivity around an asset.

Patents
Expiration dates
Exclusivity

Competitive landscape

Compare development programs by target, modality, and indication.

Competing assets
Targets
Development stage

Research & analysis

Connect source evidence and development news to your research questions.

Publications
News
Analysis

Bring the full picture into focus.

See how Gosset can support your research on CM-2489.

Explore the full profile